GH Secretagogues Explained: The Differences and How to Combine Them

GH secretagogues are what people use to get more growth hormone without injecting the hormone itself. The usual reasons are deeper sleep, better recovery and healing, and a leaner body over time. They work by getting the pituitary gland, a small gland at the base of the brain, to release more of its own growth hormone. They do not supply the hormone directly, the way injected HGH does. They fall into two families, and each family works on a different receptor. A receptor is a switch on a cell that a hormone turns on. The first family is the GHRH analogs: sermorelin, CJC-1295 and tesamorelin. The second is the GHRPs, or ghrelin mimetics: ipamorelin, GHRP-2, GHRP-6, hexarelin and MK-677.

People say "growth hormone peptide" as if it meant one thing. It does not. These compounds split into two groups that work through two different switches. Once you know the two groups, the combination questions answer themselves. You can see which ones stack, which ones just double up, and when adding a peptide to real HGH stops making sense.

This guide is a plain-English map. It covers what a GH secretagogue is, the two families and how they differ, and why pairing one from each family is the whole point. It also covers the two combinations people get wrong most often.

A quick word on what Primogen stocks. We carry the pre-mixed CJC-1295 + ipamorelin blend (the two come together, not separately), tesamorelin, and growth hormone itself. The others below each have a real use: MK-677, sermorelin, the older GHRPs and hexarelin. We cover them fairly rather than talking them down. If you want one we do not list right now, just ask. The range is open to growing.

What is a GH secretagogue?

A GH secretagogue is a compound that signals the pituitary gland to release more of its own growth hormone. It does not add hormone from outside. The pituitary already makes growth hormone. It releases it in pulses, mostly at night during deep sleep, and it makes less as we get older. A secretagogue pushes the gland to release more of its own, on its own rhythm.

That is the main difference from injecting growth hormone. As the CJC-1295 record puts it, a secretagogue relies on the pituitary gland. Exogenous GH (growth hormone given from outside the body, by injection) goes around it. With a secretagogue, the body stays in charge. That includes its brakes: the natural feedback loop that limits how high GH climbs still works. Inject somatropin and the body gets a fixed dose directly. The ceiling and the feedback are skipped.

People usually give three reasons for choosing secretagogues over HGH itself. First, they keep the natural pulse rather than flattening it. Second, they keep the body's feedback loop working (called negative feedback), so IGF-1 is less likely to run too high. IGF-1 is a growth factor the body makes in response to GH. Third, they are usually cheaper. The trade-off is strength. In drug studies, exogenous GH gives a bigger rise in GH and IGF-1. A secretagogue has a lower ceiling by design. That is the basic difference between the two approaches.

What are the two families of GH secretagogues?

The two families are GHRH analogs and GHRPs (ghrelin mimetics). What sets them apart is the receptor they act on. GHRH analogs bind the GHRH receptor. GHRPs bind the ghrelin receptor. Knowing which family a compound belongs to is most of the battle. It tells you what stacks with what.

What are GHRH analogs?

GHRH analogs copy growth hormone-releasing hormone (GHRH). This is the body's natural "make GH" signal. They bind the GHRH receptor on the pituitary, which tells it to make and release growth hormone. The members are:

• Sermorelin is the original. It is a lab-made copy of the first 29 amino acids of human GHRH. It is short-acting (cleared in minutes) and one of the weaker members of the family. It also has the easiest legal standing. Some forms have an FDA history, and it can still be prescribed in places where the others cannot.
• CJC-1295 is a tougher cousin of sermorelin. Four of its amino acids are swapped. This helps it resist an enzyme called DPP-IV, which breaks sermorelin down fast, so its pulse lasts longer. It comes in two very different versions. The no-DAC form (also sold as Mod GRF 1-29) has a half-life of roughly 30 minutes and keeps a natural pulse. Half-life is the time the body takes to clear half a dose. The DAC form binds to a protein in the blood. That stretches its half-life to 5.8 to 8.1 days (Teichman 2006), so a weekly dose keeps GH raised all week. It is the same base peptide. But the two act so differently that you should treat them as separate tools.
• Tesamorelin is the most-studied GHRH analog and the only one with full FDA approval. It is a stabilised GHRH analog, 44 amino acids long. It is approved for cutting visceral fat (deep belly fat) in HIV-associated lipodystrophy. That is the unusual shift in body fat that some HIV treatments cause. Two major Phase 3 trials back it. In pooled Phase 3 data from 816 patients, visceral fat fell by roughly 15% over 26 weeks (Falutz 2010; Falutz 2007). A separate trial found less liver fat in people with HIV and fatty liver disease, called NAFLD (Stanley 2019). Another trial reported a sign of better thinking skills in older adults (Baker 2012). Like the others, it is short-acting. It just has better evidence.

What are GHRPs and ghrelin mimetics?

GHRPs (growth-hormone-releasing peptides) and ghrelin mimetics work through the other switch. A ghrelin mimetic is a compound that copies ghrelin, the hunger hormone. Both act on the ghrelin receptor (GHS-R1a), the same one ghrelin itself uses. Switching it on releases a sharp pulse of stored GH. The members are:

• Ipamorelin is the selective one. It is a pentapeptide, meaning a peptide just five amino acids long. It triggers a GH pulse without pushing up cortisol and prolactin. Those are the stress and milk hormones that the older GHRPs also raise. This selectivity is its key feature in animal studies (Raun 1998). It is why ipamorelin is the GHRP most often run long-term. It is also the one paired with CJC-1295 in the standard blend. How it behaves in the human body is well mapped (Gobburu 1999).
• GHRP-2 is older and somewhat stronger per microgram. But it raises prolactin and cortisol along with GH. You get a strong, cheap pulse, plus those extra hormone effects.
• GHRP-6 is the appetite one. It is a strong hunger trigger. That is a drawback for most research uses, and a point of interest for research on appetite. It raises cortisol and prolactin, the same as GHRP-2.
• Hexarelin is close in structure to GHRP-6 and releases a lot of GH. But it raises cortisol and prolactin the most of the group. It also tends to stop working as well with steady use, which is called desensitising. That limits its research use, even though it looks strong on paper.
• MK-677 (ibutamoren) is the odd one out. You take it by mouth, it is not a peptide, and its half-life is roughly 24 hours. No needles. The other side of that long action is that it does not give a clean pulse. Instead it keeps GH and IGF-1 raised all day and night. That is linked to more appetite, more water retention, and a higher risk of insulin resistance than the pulsed injections. Insulin resistance means the body responds less well to insulin, so blood sugar runs higher. Of the GHRPs, MK-677 has the most clinical study history. It has been through controlled trials in humans, including in growth hormone deficiency. It is also the only oral option in the group.

GHRH analogs vs GHRPs: how do the two families differ?

GHRH analogs and GHRPs differ in three ways: the receptor they act on, the signal they copy, and their side effects. GHRH analogs set the GH pulse going through the GHRH receptor. They do little to appetite or stress hormones. GHRPs fire a sharp pulse through the ghrelin receptor. Apart from ipamorelin, they tend to raise appetite and stress hormones. The table shows them side by side.

Why is a GHRH plus a GHRP synergistic?

A GHRH analog plus a GHRP is synergistic because the two families pull on two separate levers. Synergistic means the combined effect is bigger than the two effects added together. A GHRH analog primes the pituitary and sets the pulse going. A GHRP fires a sharp release through the separate ghrelin receptor. Hit both receptors at once and the response grows.

That is exactly why CJC-1295 (no-DAC) and ipamorelin are paired, rather than treated as a choice between the two. One is a GHRH analog and the other is a GHRP. They are two different mechanisms working together. CJC-1295 adds size and length to the pulse. Ipamorelin adds the selective trigger, without the cortisol or prolactin rise of the older GHRPs. That is the reason the pre-mixed blend exists. It is one of the most widely run GH protocols for performance and longevity. Our guide to the CJC + Ipamorelin stack covers the doses, the timing and the DAC vs no-DAC choice in detail.

The rule holds in general: one GHRH plus one GHRP is where the synergy is. Tesamorelin plus ipamorelin follows the same logic, with a better-studied GHRH at the front. What does not add up is doubling up within one family. That brings us to the two questions that come up most.

Can you run CJC-1295 and tesamorelin together?

There is little point in running CJC-1295 and tesamorelin together. Both are GHRH analogs that act on the same receptor.

Because CJC-1295 and tesamorelin are both GHRH analogs, they bind the same receptor and work the same way. Combining them is not synergy. It is doubling up: knocking on one door twice instead of opening a second one. You get little extra GH for the extra cost and the extra injection. That one receptor can only be pushed so far.

To get more from a GHRH analog, the answer is not another GHRH analog. It is a GHRP, and ipamorelin is the usual selective choice. That opens the second, separate pathway, which is where the synergy is. So the sensible setup is to pick one GHRH analog and pair it with a GHRP. Choose CJC-1295 for value and a natural pulse. Or choose tesamorelin for FDA-level evidence and its focus on deep belly fat. Do not run two GHRHs side by side.

There is one narrow real-world exception. Some people use tesamorelin just for its belly-fat use, and run a CJC/ipamorelin blend on the side for general recovery. That is two products doing two jobs. It is not stacking two GHRHs for more GH. And because the two GHRH parts overlap, their effects still do not add together.

Can you run a secretagogue and HGH at the same time?

Running a secretagogue alongside exogenous HGH is usually pointless, and it can work against you. The injected HGH shuts down the body's own GH, which leaves the secretagogue little to act on.

Exogenous HGH (somatropin) is the hormone itself, delivered directly. When you inject it, the body senses the high levels of GH and IGF-1 in the blood. It then switches off its own production through negative feedback. That is how the system keeps itself in balance. A secretagogue's whole job is to coax out the body's own GH (called endogenous GH). If the injected hormone has already told the pituitary to stand down, there is very little left for a secretagogue to do. As the ipamorelin record puts it, on top of exogenous GH a secretagogue is basically a placebo.

So in most cases it is one or the other. With HGH, the GH is supplied directly, and a secretagogue adds cost without adding much. A secretagogue on its own is the gentler approach. It keeps the pulse and has a lower ceiling. It is a good choice in its own right, not a step on the way to something stronger.

The two only go together in one small, advanced niche. Some people use low-dose HGH as a base, with a secretagogue on top. This is usually tesamorelin, for its belly-fat use. That is a deliberate and expensive choice, not a starting point. The simple default is to pick one approach.

Which GH secretagogue is best?

There is no single best GH secretagogue. Each family is a tool for a different job. The right one depends on what matters most to you: the evidence, the route (injection or by mouth), or its legal standing.

• Best evidence for a single compound: tesamorelin. It is the only FDA-approved GHRH analog. It has Phase 3 data and a specific use for deep belly fat.
• Standard, balanced pairing: CJC-1295 + ipamorelin. It has one from each family, so the two work together. It is selective, and it is the most widely run.
• No needles: MK-677. The trade-off is constant (rather than pulsed) GH, more appetite, more water retention, and a need to watch blood sugar more closely.
• Appetite-focused: GHRP-6, the strongest hunger trigger of the group.
• Cheapest, easiest legal standing: sermorelin. The trade-off is that it is the weakest GHRH analog.

There is no ladder here. You do not have to earn tesamorelin by starting on sermorelin. And you do not have to move up from secretagogues to HGH. Match the tool to your goal. Think about how you feel about needles, how much you want to spend, and how hard you want to push.

How strong is the evidence for GH secretagogues?

Tesamorelin has the strongest evidence, with Phase 3 data and FDA approval. For the rest of the class, the evidence comes from how they work and from human dosing studies. Finished trials of real-world results are still missing. CJC-1295's rise in GH and IGF-1 was measured in Teichman 2006. Ipamorelin's selectivity was shown in Raun 1998, and how the body handles it in Gobburu 1999.

The only finished ipamorelin trial of results was in postoperative ileus, a slowdown of the gut after surgery. It missed its main goal (Beck 2014). So the body shape and sleep uses people run it for make sense in theory. But they have not been proven in randomised controlled trials (RCTs). The same goes for the wider reports of body shape, recovery and sleep benefits that drive demand for this class. Those reports come from practitioners and users, not RCTs. We will not present them as proven results.

There are two real cautions for the whole class.

IGF-1. Anything that keeps IGF-1 raised over time carries a theoretical long-term concern. Large population studies link higher IGF-1 to slightly higher rates of some cancers (Knuppel 2020). So this class is not suitable for anyone with active or recent cancer. IGF-1 is usually checked and kept in the upper-normal range for your age. It is not pushed above natural levels.

Blood sugar. Keeping GH raised for a long time can change how well the body responds to insulin. That is why the pulsed injections, and MK-677 most of all, call for checking fasting blood sugar and HbA1c over time. HbA1c is a measure of your average blood sugar over the past few months.

How are GH secretagogues handled and reconstituted?

The injectable GH secretagogues come as a lyophilised (freeze-dried) powder. You reconstitute them, which means mixing them with a liquid. The liquid is bacteriostatic water, the only one Primogen supplies. The peptides are made for subcutaneous use. That means a small injection into the fat just under the skin, usually on the belly. For some, an injection into muscle is an option too. MK-677 is the member you take by mouth. None of them is made for injection into a vein (IV), and we do not offer or recommend IV use.

In published studies, food blunts the GH response, mainly because of the rise in insulin after eating. That is why the pulsed injections are usually taken before bed, on an empty stomach. This lines up with the body's natural GH pulse at night. The full method for mixing and measuring is in how to reconstitute and dose.

Here is a worked example. A 5 mg vial mixed with 2 mL of bacteriostatic water gives 2.5 mg per mL. So a 250 mcg research dose is 0.1 mL. That is 10 units on a U-100 insulin syringe. If you are combining compounds, peptide stacking covers the general rules on what works well together and what just adds cost.

Referenced products

Tesamorelin

Rp 1.790.000 · 10mg

HGH

from Rp 390.000

CJC-1295 no DAC + Ipamorelin Blend

Rp 1.590.000 · 10mg